Loading...
Please wait, while we are loading the content...
Similar Documents
Comparative evaluation of efficacy and safety profile of febuxostat with allopurinol in patients with hyperuricemia and gout.
| Content Provider | CiteSeerX |
|---|---|
| Author | Agarwal, P. K. Kumar, Bijay |
| Abstract | Gout is known to be a metabolic disease mostly affecting the elderly. Treatment and management becomes all the more difficult in this age group because of presence of co-morbidity (like Hypertension, Diabetes Mellitus, Renal and Cardiovascular diseases) and concomitant use of medication which at times do not agree with the usual hypouricemic drugs used in gout. The objective of this study was to compare the effect and side effect of Allopurinol with Febuxostat, a relatively new uric acid lowering drug. Subjects between 30- 55 years having serum uric acid level> 8.0 mg were enrolled in this randomized trial to receive either Allopurinol (100 mg thrice a day) or Febuxostat (40 mg once daily) for a period of 3 months. Febuxostat (40 mg once daily) was more effective than Allopurinol (100 mg thrice a day) in lowering serum uric acid at 3 months. Serum uric acid came below 6 mg/dl in>62 % of Febuxostat treated patients as compared to Allopurinol group where it came down in only <38 % of cases. Flaring of gouty arthritis was nil in Febuxostat group while 7 patients showed drug related problem in Allopurinol group. Compliance to drug therapy was much better in Febuxostat group. |
| File Format | |
| Access Restriction | Open |
| Subject Keyword | Serum Uric Acid Mg Thrice Febuxostat Group Allopurinol Group Age Group Randomized Trial Mg Dl New Uric Acid Metabolic Disease Usual Hypouricemic Drug Drug Therapy Side Effect Cardiovascular Disease Gouty Arthritis Diabetes Mellitus Serum Uric Acid Level Concomitant Use |
| Content Type | Text |